Nov. 8, 2012
-- (ST. LOUIS)
— Mobius Therapeutics, LLC announced today the Centers for Medicare and Medicaid Services (CMS) has assigned a product-specific Healthcare Common Procedures Coding System (HCPCS) code for Mitosol® (mitomycin for solution) 0.2mg/vial, Kit for Ophthalmic Use. Mitosol is used as an adjunct to ab externo glaucoma surgery. The new J-code, J7315, becomes effective on January 1, 2013.
"This is an important milestone for Mobius Therapeutics, and we are very pleased that CMS has issued a J-code for Mitosol®," said Ed Timm, Chief Executive Officer and Founder of Mobius Therapeutics, LLC. "While it may take up to three months for the J-code to be loaded into the entire payer system, the J-code facilitates more rapid reimbursement for providers. Mitosol is manufactured under cGMP controls and provides assured dosing concentration with consistent potency and sterility. In light of the on-going concerns related to the sterility and quality assurance of sterile filled medications, Mitosol’s quality manufacturing and convenience helps providers and patients with peace of mind.”
J-codes are part of the Healthcare Common Procedure Coding System (HCPCS), and used by providers to identify medical products to facilitate reimbursement. About Mobius Therapeutics, LLC:
Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol
®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization;
the pterygium and refractive indications are awaiting approval by the Food and Drug Administration. Mobius is housed within the Center for Emerging Technologies in St. Louis, Missouri.